IP News
IP News

2023 Amendment under Discussion

AJU KIM CHANG LEE|February 8, 2023
2023 Amendment under Discussion

(1) Establishment of grounds for notification of job invention electronic documents

AJU KIM CHANG LEE

Figure 01 / 02

2023 Proposed IP Amendments

STEP 01

Patent term extension overhaul (pharma)

KIPO TF reviewing major revision of drug approval extension system, benchmarking US, EU, Japan

STEP 02

Limit on patents per drug approval

Key issue: how many patents can be extended for a single pharmaceutical product approval

STEP 03

Advanced biopharmaceuticals added

Proposed expansion of inventions subject to patent term extension to include advanced biopharmaceuticals

Key items under discussion for 2023 legislative amendments

Figure 02 / 02

Employee Invention Notices

Before Feb 15, 2023

Paper submissions only

Employee invention notifications required paper submissions only

After · From Feb 15, 2023

Electronic docs now valid

Electronic documents now valid for reporting, succession, and compensation notices under Framework Act on Electronic Commerce

Change effective February 15, 2023 under revised Invention Promotion Act

TopicsIP News

Executive Summary

(1) Establishment of grounds for notification of job invention electronic documents

When notifying employee inventions, paper submissions, including electronic documents, will be possible from February 15, 2023. With the implementation of the revised Korea Invention Promotion Act on February 15, 2023, the basis for notification of employee invention electronic documents, such as ▲ reporting of employee inventions, ▲ succession, and ▲ fair compensation, has been prepared. Accordingly, documents including electronic documents pursuant to Article 2, Subparagraph 1 of the Framework Act on Electronic Commerce can be submitted.

(2) Possibility of reorganization of the system for extending the duration of patent rights according to drug approval, etc.

In 1986, after the application system for approval of the extension of the duration of patent rights was introduced under trade pressure from the United States, it was changed to the application system for registration of extension in 1990. Since then, in 1995, the ‘Regulations on the Operation of Extension of Term of Patent Rights’ have been enacted and have been in operation.

Korean Intellectual Property Office (KIPO) has set up a TF for a major overhaul of the extension system, listened to opinions from the biopharmaceutical industry, and is promoting revision of major details by referring to overseas cases such as the US, Europe, and Japan in 2023.

The main issues are expected to be the number of patents that can be extended for one product approval, the upper limit on the duration of extended patent rights, and the addition of advanced biopharmaceuticals to inventions subject to extension.

Published

February 8, 2023 · AJU KIM CHANG LEE

Back to IP News